Patients’ baseline characteristics on admission
| Lower risk (n = 4252) | High risk (n = 7633) | p Value | |
|---|---|---|---|
| Data are mean (SD) or number (%). | |||
| ACE, angiotensin converting enzyme; CAD, coronary artery disease; Gp, glycoprotein; LMWH, low molecular weight heparin; NS, not significant. | |||
| Age (years) | 65.2 (12.1) | 66.9 (12.9) | <0.0001 |
| Men | 2557 (60.4%) | 4812 (63.5%) | 0.0009 |
| Risk factors | |||
| Hypertension | 2795 (66.1%) | 4783 (63.0%) | 0.0008 |
| Hyperlipidaemia | 2396 (56.8%) | 3363 (44.5%) | <0.0001 |
| Diabetes mellitus | 1067 (25.3%) | 1919 (25.3%) | NS |
| Smoker (current or past) | 2296 (54.2%) | 4168 (55.0%) | NS |
| History of CAD | 1814 (45.8%) | 1965 (26.7%) | <0.0001 |
| New ECG changes | 1719 (43.9%) | 5373 (74.2%) | <0.0001 |
| Preadmission medications | |||
| Aspirin | 2558 (60.2%) | 3191 (41.9%) | <0.0001 |
| β Blockers | 1903 (45.0%) | 2335 (30.7%) | <0.0001 |
| Calcium channel blockers | 1165 (27.9%) | 1639 (21.8%) | <0.0001 |
| Nitrates | 1590 (37.6%) | 1870 (24.6%) | <0.0001 |
| ACE inhibitors | 1350 (32.2%) | 2089 (27.6%) | <0.0001 |
| Statins | 1468 (34.9%) | 1608 (21.3%) | <0.0001 |
| In-hospital antithrombotic treatment | |||
| Unfractionated heparin | 1903 (45.3%) | 3942 (52.4%) | <0.0001 |
| LMWH | 2015 (48.1%) | 4215 (56.1%) | <0.0001 |
| Gp IIb/IIIa antagonists | 421 (10.0%) | 1614 (21.4%) | <0.0001 |